GlassScriptPhysician profile
Alexandra Berard Mcleod
NPI 1992588966
$631.71
in general payments reported to CMS, 2019-2025
14 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.91 · 2024: $314 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $143.42 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.34 | 2025 | Libtayo |
| Glaxosmithkline, LLC. | $68.07 | 2025 | Ojjaara |
| Daiichi Sankyo INC. | $47.59 | 2023 | Enhertu |
| Abbvie INC. | $42.14 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $34.42 | 2024-2025 | Opdualag |
| Deciphera Pharmaceuticals INC. | $33.13 | 2024 | Qinlock |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Astrazeneca Pharmaceuticals LP | $23.26 | 2025 | Calquence |
| Aveo Pharmaceuticals, INC. | $22.46 | 2024 | |
| Incyte Corporation | $19.25 | 2024 | |
| Genentech USA, INC. | $18.46 | 2024 | Gazyva, Venclexta |
| Cti Biopharma Corp. | $18.32 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $16.21 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Mcleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.